{"id":"eu-ocrevus","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Infusion-related reactions"},{"rate":"15-25","effect":"Upper respiratory tract infections"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"10-20","effect":"Nasopharyngitis"},{"rate":"variable","effect":"Immunosuppression/infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EU-Ocrevus targets CD20, a surface antigen expressed on B lymphocytes. By binding to CD20, the antibody triggers B cell destruction through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby reducing the pathogenic B cell population involved in autoimmune diseases. This mechanism reduces inflammation and autoimmune-mediated tissue damage.","oneSentence":"EU-Ocrevus is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:50.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis (relapsing and progressive forms)"},{"name":"Granulomatosis with polyangiitis (GPA)"},{"name":"Microscopic polyangiitis (MPA)"}]},"trialDetails":[{"nctId":"NCT06700343","phase":"PHASE3","title":"Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-01-13","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":444},{"nctId":"NCT06847724","phase":"PHASE3","title":"Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Sandoz","startDate":"2025-06-10","conditions":"Relapsing Multiple Sclerosis","enrollment":175},{"nctId":"NCT05906992","phase":"PHASE3","title":"A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis","status":"RECRUITING","sponsor":"Celltrion","startDate":"2024-01-11","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":512}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ocrelizumab"],"phase":"phase_3","status":"active","brandName":"EU-Ocrevus","genericName":"EU-Ocrevus","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"EU-Ocrevus is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity. Used for Multiple sclerosis (relapsing and progressive forms), Granulomatosis with polyangiitis (GPA), Microscopic polyangiitis (MPA).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}